Innate Pharma (IPHA) Current Taxes (2019 - 2025)

Innate Pharma (IPHA) has reported Current Taxes for 7 consecutive years, with $36.1 million the latest figure, recorded in Q4 2025.

• Quarterly Current Taxes fell 22.81% year-over-year to $36.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $36.1 million (down 22.81% YoY) and the FY2025 annual result came in at $36.1 million, down 22.81% from the prior year.
• Current Taxes retreated to $36.1 million in Q4 2025 per IPHA's latest filing, from $39.3 million in the prior quarter.
• Over the last five years, Current Taxes for IPHA reached as high as $67.1 million in Q2 2022 and fell as low as $36.1 million in Q4 2025.
• A 5-year average of $48.6 million and a median of $47.2 million in 2024 frame the typical range for Current Taxes.
• Annual changes were most pronounced in 2021 — Current Taxes plunged 99.64% — and 2022, when it jumped 60.58%.
• Year by year, Current Taxes stood at $37.5 million in 2021, then jumped by 60.58% to $60.3 million in 2022, then decreased by 15.02% to $51.2 million in 2023, then declined by 8.67% to $46.8 million in 2024, then declined by 22.81% to $36.1 million in 2025.
• According to Business Quant data, Current Taxes over the past three periods registered $36.1 million, $39.3 million, and $46.8 million for Q4 2025, Q2 2025, and Q4 2024 respectively.